Tadalafil - Erectile dysfunction combination therapy
You are here : Home > Formulary Search > Tadalafil - Erectile dysfunction combination therapy
I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.
Documentation
PAD Profile
ChemicalSubstance :
Tadalafil
Indication :
Erectile dysfunction combination therapy
Group Name :
Keywords :
Phosphodiesterase type 5 inhibitors, ED, Impotence
Brand Names Include :
Cialis
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
2
Other Indications
Below are listed other indications that Tadalafil is used to treat.
Other Drugs
Below are listed other drugs that are used to treat Erectile dysfunction combination therapy.
Committee Recommendations (2)
At the Surrey and North-West Sussex Area Prescribing Committee (APC) held in June 2020, it was decided that all BLACK status drugs would have their review dates extended for 5 years without the need for a review.
If a clinician or provider wishes to change the traffic light status of any BLACK drug then they will need to submit a paper for change as per usual APC process.
Use of both oral and non-oral combination treatments for erectile dysfunction in patients who had not responded or had a sub-optimal response to monotherapy was considered.The network members concurred that based on the limited available evidence, noting the feedback from clinicians, that combination treatments should not be supported and a BLACK status should be given on the PAD.Please see policy statement from June 2012